Table 1.
Association between YB-1 staining results and prostate cancer phenotype.
| Parameter | N evaluable | Cytoplasmic YB-1 staining (%) | P value | Nuclear accumulation (%) | P value | |||
|---|---|---|---|---|---|---|---|---|
| Negative | Weak | Moderate | Strong | |||||
| All cancers | 6,935 | 14.2 | 29.6 | 43.3 | 13.0 | 29.1 | ||
| Tumour stage | 0.0165 | <0.0001 | ||||||
| pT2 | 4,359 | 14.9 | 29.1 | 43.4 | 12.7 | 26.6 | ||
| pT3a | 1,663 | 11.6 | 30.7 | 43.8 | 13.9 | 33.1 | ||
| pT3b-pT4 | 887 | 11.8 | 30.6 | 44.5 | 13.1 | 37.0 | ||
| Gleason grade | <0.0001 | <0.0001 | ||||||
| ≤3 + 3 | 1,523 | 19.9 | 28.3 | 39.7 | 12.1 | 20.2 | ||
| 3 + 4 | 3,567 | 12.1 | 30.4 | 44.4 | 13.1 | 30.4 | ||
| 3 + 4 tertiary 5 | 296 | 15.3 | 25.8 | 46.8 | 12.1 | 41.5 | ||
| 4 + 3 | 603 | 11.1 | 26.0 | 47.1 | 15.8 | 33.9 | ||
| 4 + 3 tertiary 5 | 424 | 9.3 | 29.2 | 48.2 | 13.3 | 41.9 | ||
| ≥4 + 4 | 238 | 11.8 | 31.9 | 44.1 | 12.2 | 43.8 | ||
| Lymph node metastasis | 0.8530 | 0.0056 | ||||||
| N0 | 3,974 | 12.8 | 30.2 | 43.9 | 13.1 | 30.4 | ||
| N+ | 364 | 12.9 | 31.9 | 43.4 | 11.8 | 38.5 | ||
| Preoperative PSA level (ng/ml) | <0.0001 | 0.008 | ||||||
| <4 | 803 | 11.5 | 29.3 | 44.7 | 14.6 | 30.1 | ||
| 4–10 | 4,165 | 13.0 | 28.7 | 44.3 | 13.9 | 28.9 | ||
| 10–20 | 1,384 | 15.5 | 30.9 | 43.1 | 10.5 | 30.0 | ||
| >20 | 499 | 18.2 | 34.5 | 38.1 | 9.2 | 31.8 | ||
| Surgical margin | 0.1780 | 0.5781 | ||||||
| Negative | 5,481 | 13.7 | 29.2 | 43.7 | 13.4 | 29.2 | ||
| Positive | 1,338 | 13.2 | 31.8 | 43.2 | 11.7 | 30.5 | ||